Released Mar 26, 2015, after the close
10-K filed Mar 27, 2015, 86 days after period end · 0001019687-15-001115
Q4 2014 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$6.75M$6.75M derived+2.7% vs Q4 2013+12.4% vs Q3 2014
Net Income-$1.72M-$1.72M derivedN/M vs Q4 2013N/M vs Q3 2014
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$1,513,000N/M
Operating Cash Flowderived-$2,949,000N/M
Free Cash Flowderived-$3,165,000N/M
Margins · derived
Operating margin-22.4%−16.3 pt vs Q4 2013
Net margin-25.5%−20.1 pt vs Q4 2013
What the release said
The release
Same quarter
| Metric | Q4 2014dderived from reported figures | Q4 2013dderived from reported figures | Q4 2012 | Q4 2011 |
|---|---|---|---|---|
| Revenue | $6.75M | $6.58M | $5.93M | $6.10M |
| Net Income | -$1.72M | -$351.00K | $629.00K | -$1.04M |
| EPS Diluted | — | — | $0.01 | -$0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR